AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.